Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

Press Release

Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting


SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated and inflammatory conditions, including the ongoing ELEVATE UC Phase 3 trial that was initiated this year.  These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey.

"Steady-state etrasimod trough concentrations were achieved and maintained from weeks 1 to 12 in patients with moderately to severely active ulcerative colitis treated with 1 or 2 mg etrasimod once-daily. Statistically significant exposure-response relationships favoring 2 mg dosing were demonstrated, with reductions from baseline in circulating lymphocyte count and improvements in modified Mayo Clinic Score," stated Dr. Preston Klassen, Executive Vice President, Head of Research & Development at Arena.  "In addition to previously reported dose-response data from OASIS, these new findings further strengthen the etrasimod 2 mg dosing regimen chosen for our Phase 3 ELEVATE UC program."

Presentation Details:
Title: Steady-State Trough Concentrations and Their Relationship to Selected Demographic and Clinical Response Measures in Etrasimod-Treated Patients With Moderately-to-Severely Active Ulcerative Colitis 

These data will be encored at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) 2019 Annual Meeting, and the American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Meeting.

About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune-mediated and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease (CD), as well as in programs for other indications such as atopic dermatitis. Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.

Arena has additional license agreements and partnerships, including with United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension), Everest Medicines Limited (etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be identified by introductory words such as "in development for," "will," "driven to," "potentially," "potential," "evaluating," or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements about Arena's participation in upcoming meetings; the opportunity, development and potential of etrasimod, including the dosing regimen in Arena's Phase 3 ELEVATE UC Program; Arena's drive; and the potential of Arena's assets, programs, licenses, and partnerships. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer                         

Media Contact:
Matt Middleman, MD
LifeSci Public Relations


Arena Pharmaceuticals Logo




Cision View original content to download multimedia:

SOURCE Arena Pharmaceuticals, Inc.